AIG
OCUL icon

American International Group’s Ocular Therapeutix OCUL Stock Holding History

American International Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-56,981
Closed -$519K – 1840
2024
Q1 		$519K Buy
56,981
+17,251
+43% +$122K ﹤0.01% 1630
2023
Q4 		$177K Buy
39,730
+783
+2% +$2.31K ﹤0.01% 2232
2023
Q3 		$122K Buy
38,947
+1,384
+4% +$5.66K ﹤0.01% 2398
2023
Q2 		$194K Buy
37,563
+374
+1% +$2.22K ﹤0.01% 2188
2023
Q1 		$196K Buy
37,189
+740
+2% +$3.51K ﹤0.01% 2117
2022
Q4 		$102K Sell
36,449
-133
-0.4% -$440 ﹤0.01% 2504
2022
Q3 		$152K Buy
36,582
+517
+1% +$2.6K ﹤0.01% 2312
2022
Q2 		$145K Sell
36,065
-1,993
-5% -$7.53K ﹤0.01% 2378
2022
Q1 		$188K Sell
38,058
-2,679
-7% -$14.8K ﹤0.01% 2279
2021
Q4 		$284K Sell
40,737
-1,218
-3% -$9.46K ﹤0.01% 2155
2021
Q3 		$420K Sell
41,955
-997
-2% -$11.2K ﹤0.01% 1976
2021
Q2 		$609 Buy
42,952
+473
+1% +$7.19K ﹤0.01% 1795
2021
Q1 		$697 Buy
42,479
+2,607
+7% +$50.2K ﹤0.01% 1657
2020
Q4 		$825 Buy
39,872
+3,702
+10% +$55K ﹤0.01% 1495
2020
Q3 		$275K Buy
36,170
+4,815
+15% +$40K ﹤0.01% 1939
2020
Q2 		$261K Buy
31,355
+6,352
+25% +$42.1K ﹤0.01% 1974
2020
Q1 		$124K Sell
25,003
-1,445
-5% -$7.13K ﹤0.01% 2189
2019
Q4 		$104K Buy
26,448
+267
+1% +$928 ﹤0.01% 2603
2019
Q3 		$80K Buy
26,181
+2,252
+9% +$10.1K ﹤0.01% 2723
2019
Q2 		$105K Buy
23,929
+1,255
+6% +$4.65K ﹤0.01% 2647
2019
Q1 		$90K Buy
22,674
+691
+3% +$2.78K ﹤0.01% 2670
2018
Q4 		$87K Sell
21,983
-169
-0.8% -$931 ﹤0.01% 2667
2018
Q3 		$152K Buy
22,152
+1,139
+5% +$7.15K ﹤0.01% 2599
2018
Q2 		$142K Buy
21,013
+2,579
+14% +$17.7K ﹤0.01% 2573
2018
Q1 		$120K Buy
18,434
+3,249
+21% +$18.3K ﹤0.01% 2563
2017
Q4 		$68K Buy
15,185
+70
+0.5% +$358 ﹤0.01% 2877
2017
Q3 		$93K Buy
15,115
+1,130
+8% +$7.28K ﹤0.01% 2691
2017
Q2 		$130K Buy
13,985
+2,847
+26% +$27.6K ﹤0.01% 2565
2017
Q1 		$103K Buy
11,138
+844
+8% +$7.03K ﹤0.01% 2569
2016
Q4 		$86K Sell
10,294
-27
-0.3% -$209 ﹤0.01% 2683
2016
Q3 		$70.9K Buy
10,321
+15
+0.1% +$91 ﹤0.01% 2796
2016
Q2 		$51K Buy
10,306
+2,674
+35% +$26.5K ﹤0.01% 2944
2016
Q1 		$74K Hold
7,632
– – ﹤0.01% 3632
2015
Q4 		$72K Sell
7,632
-14
-0.2% -$151 ﹤0.01% 3703
2015
Q3 		$108K Buy
7,646
+9
+0.1% +$181 ﹤0.01% 3426
2015
Q2 		$161K Buy
7,637
+4,022
+111% +$99.7K ﹤0.01% 3214
2015
Q1 		$152K Hold
3,615
– – ﹤0.01% 3204
2014
Q4 		$85K Buy
+3,615
New +$60.8K ﹤0.01% 3712

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

American International Group's OCUL Position: Q2 2024 in Review

American International Group sold out of Ocular Therapeutix (OCUL) in Q2 2024, closing a stake of 56,981 shares — an estimated $519K sold.

American International Group first reported a position in OCUL in Q4 2014 and held it in 38 quarters. The position peaked at $519K in Q1 2024. 150 funds tracked by Wall St. Rank hold OCUL as of Q2 2024.

  • American International Group reported no remaining Ocular Therapeutix position as of Q2 2024 after selling out during the quarter.
  • American International Group sold 56,981 Ocular Therapeutix shares in Q2 2024, an estimated $519K.
  • American International Group first reported a position in Ocular Therapeutix in Q4 2014 and held it in 38 quarters.
  • American International Group's Ocular Therapeutix position peaked at $519K in Q1 2024.
  • 150 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.